This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Monday's Health Winners & Losers

Health stocks kept slightly green Monday amid an array of news, including trial updates, turnover and turmoil in general.

First, Acorda Therapeutics (ACOR) tacked on 25% to $27.20 Monday after the company said a study showed its experimental multiple sclerosis drug Fampridine didn't cause an increase in the electrocardiographic QT interval in comparison to placebo.

The Food and Drug Administration requires companies to conduct QT studies on drugs because changes to the QT interval, a measure of time between waves in the heart's electrical cycle, can indicate risk of cardiac arrhythmias. The company expects data in the second quarter of this year from a second phase III study of the drug, which is currently being studied for improving walking ability in people with multiple sclerosis.

Another stock up on high volume, Medivation (MDVN) said that after discussing midstage trial results with the FDA it now plans to move Alzheimer's treatment candidate Dimebon into late-stage development.

The company is holding a conference call Monday at 4:30 p.m. to discuss the decision. Watch for more on Medivation and this call from TheStreet.com senior columnist Adam Feuerstein. Shares were up 12.2% at $16.66.

Meanwhile, inching down a few percentage points, Biogen Idec (BIIB) said Monday that activist investor Carl Icahn has nominated three people to the biotech company's board.

"We are taking this action because we believe that Biogen's recent purported attempt to find a suitor was not conducted in a way to enhance the success of the endeavor. We believe that the process was flawed in a number of key respects and that the process was run to placate us and other large shareholders who we believe asked for Biogen to find a buyer," Icahn said in a press release Monday.

His three nominees include ImClone Systems (IMCL) board members Alexander Denner and Richard Mulligan. Denner is Icahn's lead advisor and also a board member at Adventrx (ANX), and Mulligan is the director of the Gene Therapy Institute and an endowed professor of genetics at Harvard. The third proposed addition is Anne Young, chief of neurology at Massachusetts General Hospital and the Julieanne Dorn Professor of Neurology at Harvard Medical School. Biogen ticked down 1.3% to $58.13.

On the ratings side, Jeffries and Co. analyst Eun Yang upgraded Medarex (MEDX) to buy from hold, considering the long-term outlook for its cancer-treating compounds. The stock took a beating last December when the company's ipilimumab failed to affect any shrinkage of tumors in at least 10% of patients in a study reported. However, Yang noted that the drug could eventually show an improvement in overall survival rate.

Medarex is developing Ipilimumab with Bristol-Myers Squibb (BMY) and is also entitled to a 15% royalty on sales of tremelimumab, a similar product that Pfizer (PFE) is developing. Late-stage data on the class of drugs, known as CTLA-4 inhibitors, are expected in 2009, and with potential commercial launches that year or the next, Yang sees Medarex poised to receive $300 million in royalties annually.

Medarex shares edged up 4% to $9.59, but are still nearly 47% lower than the stock's 52-week high. Medarex, Biogen and Acorda are all components of the Nasdaq biotechnology index, which was up 1.1% at 800.46.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,042.90 -28.32 -0.17%
S&P 500 1,972.29 -5.51 -0.28%
NASDAQ 4,493.39 -12.4620 -0.28%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs